BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996;93:1860-1870. [PMID: 8635265 DOI: 10.1161/01.cir.93.10.1860] [Cited by in Crossref: 198] [Cited by in F6Publishing: 213] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Hammoud A, Tikhomirov A, Briko A, Volkov A, Karapetyan A, Shchukin S. Evaluation of the Information Content for Determining the Vascular Tone Type of the Lower Extremities in Varicose Veins: A Case Study. Biosensors (Basel) 2023;13. [PMID: 36671931 DOI: 10.3390/bios13010096] [Reference Citation Analysis]
2 Al Attar AA, Fahed GI, Hoballah MM, Pedersen S, El-yazbi AF, Nasser SA, Bitto A, Orekhov AN, Eid AH. Mechanisms underlying the effects of caloric restriction on hypertension. Biochemical Pharmacology 2022;200:115035. [DOI: 10.1016/j.bcp.2022.115035] [Reference Citation Analysis]
3 Kaze AD, Gao X, Musani SK, Bidulescu A, Bertoni AG, Abdalla M, Echouffo-Tcheugui JB. Association of plasma endothelin-1 with blood pressure progression among Blacks: The Jackson Heart Study. Am Heart J 2022;246:144-51. [PMID: 34986393 DOI: 10.1016/j.ahj.2021.12.016] [Reference Citation Analysis]
4 Hammoud A, Tikhomirov A, Myasishcheva G, Shaheen Z, Volkov A, Briko A, Shchukin S. Multi-Channel Bioimpedance System for Detecting Vascular Tone in Human Limbs: An Approach. Sensors (Basel) 2021;22:138. [PMID: 35009681 DOI: 10.3390/s22010138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Nakamura N, Muraoka I. Effects of Greater Central Arterial Stiffness on Cardiovagal Baroreflex Sensitivity in Resistance-Trained Men. Sports Med Open 2021;7:77. [PMID: 34698951 DOI: 10.1186/s40798-021-00367-x] [Reference Citation Analysis]
6 Torres Crigna A, Link B, Samec M, Giordano FA, Kubatka P, Golubnitschaja O. Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. EPMA J 2021;:1-41. [PMID: 34367381 DOI: 10.1007/s13167-021-00248-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
7 Alcendor DJ. Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer's Disease. J Pers Med 2020;10:E199. [PMID: 33126567 DOI: 10.3390/jpm10040199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ge X, Liu Y, Yin Z, Tu S, Fan Y, Vassilevski Y, Simakov S, Liang F. Comparison of Instantaneous Wave-Free Ratio (iFR) and Fractional Flow Reserve (FFR) with respect to Their Sensitivities to Cardiovascular Factors: A Computational Model-Based Study. J Interv Cardiol 2020;2020:4094121. [PMID: 32508540 DOI: 10.1155/2020/4094121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hougaard A, Younis S, Iljazi A, Haanes KA, Lindberg U, Vestergaard MB, Amin FM, Sugimoto K, Kruse LS, Ayata C, Ashina M. Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers. J Cereb Blood Flow Metab 2020;40:1685-94. [PMID: 31500524 DOI: 10.1177/0271678X19874295] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
10 Liu L, Urch B, Szyszkowicz M, Evans G, Speck M, Van Huang A, Leingartner K, Shutt RH, Pelletier G, Gold DR, Brook JR, Godri Pollitt K, Silverman FS. Metals and oxidative potential in urban particulate matter influence systemic inflammatory and neural biomarkers: A controlled exposure study. Environ Int 2018;121:1331-40. [PMID: 30420132 DOI: 10.1016/j.envint.2018.10.055] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
11 Mazidi M, Speakman JR. Impact of Obesity and Ozone on the Association Between Particulate Air Pollution and Cardiovascular Disease and Stroke Mortality Among US Adults. J Am Heart Assoc 2018;7:e008006. [PMID: 29848499 DOI: 10.1161/JAHA.117.008006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
12 De Lima JJG. Kidney and Endothelium. Endothelium and Cardiovascular Diseases 2018. [DOI: 10.1016/b978-0-12-812348-5.00027-1] [Reference Citation Analysis]
13 Li K, Lindauer C, Haase R, Rüdiger H, Reichmann H, Reuner U, Ziemssen T. Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up. Front Physiol 2017;8:778. [PMID: 29066979 DOI: 10.3389/fphys.2017.00778] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Patel H, Alkhawam H, Madanieh R, Shah N, Kosmas CE, Vittorio TJ. Aerobic vs anaerobic exercise training effects on the cardiovascular system. World J Cardiol 2017; 9(2): 134-138 [PMID: 28289526 DOI: 10.4330/wjc.v9.i2.134] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 14.7] [Reference Citation Analysis]
15 Nishiyama SK, Zhao J, Wray DW, Richardson RS. Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction. J Appl Physiol (1985) 2017;122:354-60. [PMID: 27909229 DOI: 10.1152/japplphysiol.00772.2016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
16 Chan EA, Buckley B, Farraj AK, Thompson LC. The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction. Pharmacol Ther 2016;165:63-78. [PMID: 27222357 DOI: 10.1016/j.pharmthera.2016.05.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
17 Masaki T, Sawamura T. Endothelin and endothelial dysfunction. Proc Jpn Acad Ser B Phys Biol Sci 2006;82:17-24. [PMID: 25792766 DOI: 10.2183/pjab.82.17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
18 Liu L, Urch B, Poon R, Szyszkowicz M, Speck M, Gold DR, Wheeler AJ, Scott JA, Brook JR, Thorne PS, Silverman FS. Effects of ambient coarse, fine, and ultrafine particles and their biological constituents on systemic biomarkers: a controlled human exposure study. Environ Health Perspect 2015;123:534-40. [PMID: 25616223 DOI: 10.1289/ehp.1408387] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
19 Bender SB, de Beer VJ, Tharp DL, van Deel ED, Bowles DK, Duncker DJ, Laughlin MH, Merkus D. Reduced contribution of endothelin to the regulation of systemic and pulmonary vascular tone in severe familial hypercholesterolaemia. J Physiol 2014;592:1757-69. [PMID: 24421352 DOI: 10.1113/jphysiol.2013.267351] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
20 Erbas D. Physiological Importance of Endothelium. Endothelium 2013. [DOI: 10.1201/b14907-2] [Reference Citation Analysis]
21 Rautureau Y, Schiffrin EL. Endothelin system: roles in hypertension. Hypertension 2013. [DOI: 10.2217/ebo.12.169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Saha A, G.v. B, Babu MF, D R, Banerjea I, Jose J. A STUDY OF SERUM NITROUS OXIDE IN HYPERTENSIVES AND NORMOTENSIVES OF KONASEEMA AREA OF EAST GODAVARI DISTRICT: A FUTURE MARKER OF HYPERTENSION? jemds 2013;2:3803-3810. [DOI: 10.14260/jemds/764] [Reference Citation Analysis]
23 Pollock DM, Boesen EI. Endothelin in the Kidney. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2011;3:1-88. [DOI: 10.4199/c00042ed1v01y201110isp028] [Reference Citation Analysis]
24 Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 2011;301:H689-95. [PMID: 21666117 DOI: 10.1152/ajpheart.00206.2011] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 8.0] [Reference Citation Analysis]
25 Neerhof MG, Synowiec S, Khan S, Thaete LG. Pathophysiology of chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat. Hypertens Pregnancy 2011;30:28-36. [PMID: 21265058 DOI: 10.3109/10641950903322915] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
26 Chan SY, Loscalzo J. Endothelial Regulation of Pulmonary Vascular Tone. Textbook of Pulmonary Vascular Disease 2011. [DOI: 10.1007/978-0-387-87429-6_11] [Reference Citation Analysis]
27 Kawanabe Y, Nauli SM. Endothelin. Cell Mol Life Sci 2011;68:195-203. [PMID: 20848158 DOI: 10.1007/s00018-010-0518-0] [Cited by in Crossref: 112] [Cited by in F6Publishing: 122] [Article Influence: 8.6] [Reference Citation Analysis]
28 Lunnon MW, Wallace SML, Palmer JE, Francis-lang A, Laurijssens BE, Mistry P, Albala B, Nagafuji T, Wilkinson IB, Maltby K. Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ETA) antagonist, in the human forearm blood flow model. British Journal of Clinical Pharmacology 2010;69:252-261. [DOI: 10.1111/j.1365-2125.2009.03590.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Dimitrijevic I, Ekelund U, Edvinsson ML, Edvinsson L. Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome. Heart Vessels 2009;24:393-8. [PMID: 20108069 DOI: 10.1007/s00380-008-1136-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
30 Zhou J, Zhu Y, Cheng M, Dinesh D, Thorne T, Poh KK, Liu D, Botros C, Tang YL, Reisdorph N, Kishore R, Losordo DW, Qin G. Regulation of vascular contractility and blood pressure by the E2F2 transcription factor. Circulation 2009;120:1213-21. [PMID: 19752322 DOI: 10.1161/CIRCULATIONAHA.109.859207] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
31 Palmer JC, Baig S, Kehoe PG, Love S. Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol 2009;175:262-70. [PMID: 19541930 DOI: 10.2353/ajpath.2009.081054] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 5.6] [Reference Citation Analysis]
32 Resch H, Garhofer G, Fuchsjäger-Mayrl G, Hommer A, Schmetterer L. Endothelial dysfunction in glaucoma. Acta Ophthalmol 2009;87:4-12. [PMID: 18507728 DOI: 10.1111/j.1755-3768.2007.01167.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 137] [Article Influence: 8.3] [Reference Citation Analysis]
33 Neuhofer W. Method for diagnosis of a disease involving an anti-endothelin receptor antibody. Expert Opin Med Diagn 2008;2:875-878. [DOI: 10.1517/17530059.2.7.875] [Reference Citation Analysis]
34 Piechota M, Banach M, Jacoń A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 2008;13:155-81. [PMID: 17965966 DOI: 10.2478/s11658-007-0046-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
35 Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19. [PMID: 17965745 DOI: 10.1038/sj.bjp.0707516] [Cited by in Crossref: 133] [Cited by in F6Publishing: 137] [Article Influence: 8.3] [Reference Citation Analysis]
36 Dales R, Liu L, Szyszkowicz M, Dalipaj M, Willey J, Kulka R, Ruddy TD. Particulate air pollution and vascular reactivity: the bus stop study. Int Arch Occup Environ Health 2007;81:159-64. [PMID: 17492462 DOI: 10.1007/s00420-007-0199-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
37 Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2007;47:731-759. [PMID: 17002597 DOI: 10.1146/annurev.pharmtox.47.120505.105134.contrasting] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007;47:731-59. [PMID: 17002597 DOI: 10.1146/annurev.pharmtox.47.120505.105134] [Cited by in Crossref: 204] [Cited by in F6Publishing: 210] [Article Influence: 12.8] [Reference Citation Analysis]
39 Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol 2006;:295-329. [PMID: 16999223 DOI: 10.1007/3-540-32967-6_9] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 4.9] [Reference Citation Analysis]
40 Spieker LE, Flammer AJ, Lüscher TF. The vascular endothelium in hypertension. Handb Exp Pharmacol 2006;:249-83. [PMID: 16999229 DOI: 10.1007/3-540-36028-x_8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
41 Tripathi D, Therapondos G, Ferguson JW, Newby DE, Webb DJ, Hayes PC. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55:1290-5. [PMID: 16434427 DOI: 10.1136/gut.2005.077453] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
42 Dhaun N, Strachan FE, Newby DE, Johnston NR, Ford NF, Hammett JL, Palmisano M, Webb DJ. Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. Br J Clin Pharmacol. 2005;60:611-622. [PMID: 16305585 DOI: 10.1111/j.1365-2125.2005.02503.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
43 Alonso D, Radomski MW. The Nitric Oxide-Endothelin-1 Connection. The Role of Nitric Oxide in Heart Failure. [DOI: 10.1007/1-4020-7960-5_13] [Reference Citation Analysis]
44 Anderson TJ. Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction. The Role of Nitric Oxide in Heart Failure. [DOI: 10.1007/1-4020-7960-5_5] [Reference Citation Analysis]
45 Webb D, Stephen Waring W. Antihypertensive Drugs. Clinical Trials of Drugs and Biopharmaceuticals 2005. [DOI: 10.1201/9781420039146.ch14] [Reference Citation Analysis]
46 Leslie SJ, Spratt JC, McKee SP, Strachan FE, Newby DE, Northridge DB, Denvir MA, Webb DJ. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart 2005;91:914-9. [PMID: 15958361 DOI: 10.1136/hrt.2004.040386] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
47 Vanmolkot FH, de Hoon JN. Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography. Br J Clin Pharmacol 2005;59:387-97. [PMID: 15801933 DOI: 10.1111/j.1365-2125.2005.02333.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
48 Subratty AH, Gunny FB. Aprotinin suppresses ACE-inhibitor cough triggered by TAME-esterase. Med Hypotheses 2004;63:662-6. [PMID: 15325012 DOI: 10.1016/j.mehy.2003.11.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Schiffrin EL. Endothelin Antagonists. Hypertension 2005. [DOI: 10.1016/b978-0-7216-0258-5.50159-9] [Reference Citation Analysis]
50 Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003;8:107-15. [PMID: 12652164 DOI: 10.1023/a:1022155206928] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 3.9] [Reference Citation Analysis]
51 Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003;8:71-86. [PMID: 12652161 DOI: 10.1023/a:1022199021949] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 5.4] [Reference Citation Analysis]
52 Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002;136:1146-52. [PMID: 12163347 DOI: 10.1038/sj.bjp.0704815] [Cited by in Crossref: 146] [Cited by in F6Publishing: 152] [Article Influence: 7.3] [Reference Citation Analysis]
53 Rasmussen M, Poulsen PH, Treiber A, Delahaye S, Tankisi A, Cold GE, Therkelsen K, Gjedde A, Astrup J. No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. Acta Anaesthesiol Scand 2003;47:200-7. [PMID: 12631050 DOI: 10.1034/j.1399-6576.2003.00019.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
54 Strachan FE, Newby DE, Sciberras DG, McCrea JB, Goldberg MR, Webb DJ. Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography. Br J Clin Pharmacol 2002;54:386-94. [PMID: 12392586 DOI: 10.1046/j.1365-2125.2002.01653.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
55 Yang LL, Husain M, Stewart DJ. The role of endothelin-1 in myocardial inflammation and fibrosis. Inflammation and Cardiac Diseases 2003. [DOI: 10.1007/978-3-0348-8047-3_22] [Reference Citation Analysis]
56 Henrion D, Benessiano J, Iglarz M, Philip I, Levy BI. Genetic determinants of vascular reactivity. Curr Hypertens Rep 2002;4:41-8. [PMID: 11790291 DOI: 10.1007/s11906-002-0052-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
57 McElvy S, Greenberg S, Baker RS, Khoury J, Clark KE. Effect of Ro 61-1790, a selective endothelin-A receptor antagonist, on systemic and uterine hemodynamics and fetal oxygenation in sheep. Am J Obstet Gynecol 2002;186:55-60. [PMID: 11810085 DOI: 10.1067/mob.2002.118159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001;134:648-54. [PMID: 11588120 DOI: 10.1038/sj.bjp.0704304] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 2.7] [Reference Citation Analysis]
59 Taddei S, Virdis A, Ghiadoni L, Sudano I, Magagna A, Salvetti A. Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev 2001;6:277-85. [PMID: 11447302 DOI: 10.1023/a:1011400124060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 1.5] [Reference Citation Analysis]
60 Lavallée M, Takamura M, Parent R, Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 2001;6:265-76. [PMID: 11447301 DOI: 10.1023/a:1011448007222] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 2.6] [Reference Citation Analysis]
61 Wiley KE, Davenport AP. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol 2001;133:568-74. [PMID: 11399674 DOI: 10.1038/sj.bjp.0704119] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
62 Donckier JE. Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension. Heart Fail Rev 2001;6:253-64. [PMID: 11447300 DOI: 10.1023/a:1011419223152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
63 Henriksen JH, Møller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut 2001;49:112-8. [PMID: 11413119 DOI: 10.1136/gut.49.1.112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
64 Wiley KE, Davenport AP. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br J Pharmacol 2001;132:213-20. [PMID: 11156580 DOI: 10.1038/sj.bjp.0703834] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.4] [Reference Citation Analysis]
65 Gray GA, Mickley EJ, Webb DJ, McEwan PE. Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction. Br J Pharmacol 2000;130:1735-44. [PMID: 10952661 DOI: 10.1038/sj.bjp.0703503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
66 Masaki T. Historical Perspective and Introduction to the Endothelin Family of Peptides. Endothelin and Its Inhibitors 2001. [DOI: 10.1007/978-3-642-56899-2_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
67 Leslie SJ, Webb DJ. Endothelin Ligands and their Experimental Effects Within the Human Circulation. Endothelin and Its Inhibitors 2001. [DOI: 10.1007/978-3-642-56899-2_19] [Reference Citation Analysis]
68 Kyriakides ZS, Kremastinos DT, Bofilis E, Tousoulis D, Antoniadis A, Webb DJ. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart 2000;84:176-82. [PMID: 10908255 DOI: 10.1136/heart.84.2.176] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 1.5] [Reference Citation Analysis]
69 Verhaar MC, Grahn AY, Van Weerdt AW, Honing ML, Morrison PJ, Yang YP, Padley RJ, Rabelink TJ. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol 2000;49:562-73. [PMID: 10848720 DOI: 10.1046/j.1365-2125.2000.00171.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 1.8] [Reference Citation Analysis]
70 Schneider MP, Hilgers KF, Klingbeil AU, John S, Veelken R, Schmieder RE. Plasma endothelin is increased in early essential hypertension. American Journal of Hypertension 2000;13:579-85. [DOI: 10.1016/s0895-7061(99)00260-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
71 Prendergast B, Newby DE, Wilson LE, Webb DJ, Mankad PS. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 1999;82:505-8. [PMID: 10490569 DOI: 10.1136/hrt.82.4.505] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
72 Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 1999;96:11496-500. [PMID: 10500205 DOI: 10.1073/pnas.96.20.11496] [Cited by in Crossref: 110] [Cited by in F6Publishing: 114] [Article Influence: 4.6] [Reference Citation Analysis]
73 H??yry P. RELAX-RELAX. Transplantation 1999;68:729-730. [DOI: 10.1097/00007890-199909270-00003] [Reference Citation Analysis]
74 Newby D, Strachan F, Johnston N, Webb D. Endothelin-1 does not contribute to the release of tissue plasminogen activator in vivo in man. Fibrinolysis and Proteolysis 1999;13:185-91. [DOI: 10.1016/s0268-9499(99)90070-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
75 Masaki T, Ninomiya H, Sakamoto A, Okamoto Y. Structural basis of the function of endothelin receptor. Muscle Physiology and Biochemistry 1999. [DOI: 10.1007/978-1-4615-5543-8_19] [Reference Citation Analysis]
76 Warner TD. Endothelin Receptors and Ligands. Pulmonary Actions of the Endothelins 1999. [DOI: 10.1007/978-3-0348-8821-9_2] [Reference Citation Analysis]
77 Werdehoff SG, Moore RB, Hoff CJ, Fillingim E, Hackman AM. Elevated plasma endothelin-1 levels in sickle cell anemia: Relationships to oxygen saturation and left ventricular hypertrophy. Am J Hematol 1998;58:195-9. [DOI: 10.1002/(sici)1096-8652(199807)58:3<195::aid-ajh6>3.0.co;2-m] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 1.6] [Reference Citation Analysis]
78 Dupuis J, Cernacek P, Tardif J, Stewart DJ, Gosselin G, Dyrda I, Bonan R, Crépeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. American Heart Journal 1998;135:614-20. [DOI: 10.1016/s0002-8703(98)70276-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 3.1] [Reference Citation Analysis]
79 Warner TD. The Development of Specific Endothelin-Receptor Antagonists. Endothelin 1998. [DOI: 10.1007/978-1-4757-2783-8_7] [Reference Citation Analysis]
80 Ohlstein EH, Elliott JD, Brooks DP. Endothelin and Cardiovascular Function. Endocrinology of Cardiovascular Function 1998. [DOI: 10.1007/978-1-4615-5569-8_11] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
81 Evans RR, Dipette DJ. New or developing antihypertensive agents: . Current Opinion in Cardiology 1997;12:382-8. [DOI: 10.1097/00001573-199707000-00006] [Reference Citation Analysis]
82 Love MP, McMurray JJ. Endothelin in heart failure: a promising therapeutic target? Heart 1997;77:93-4. [PMID: 9068384 DOI: 10.1136/hrt.77.2.93] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
83 Willems H. Update on endothelins. Drug Discovery Today 1997;2:85-7. [DOI: 10.1016/s1359-6446(97)84784-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
84 Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-4. [PMID: 8886414 DOI: 10.1111/j.1476-5381.1996.tb15987.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 1.9] [Reference Citation Analysis]
85 Niranjan V, Télémaque S, deWit D, Gerard RD, Yanagisawa M. Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest 1996;98:2364-72. [PMID: 8941655 DOI: 10.1172/JCI119049] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
86 Haynes WG, Webb DJ. The Endothelins. Molecular and Cellular Endocrinology 1997. [DOI: 10.1016/s1569-2582(97)80171-7] [Reference Citation Analysis]
87 Webb DJ. Endothelin in Human Cardiovascular Physiology and Pathophysiology. Endothelial Function in Hypertension 1997. [DOI: 10.1007/978-3-642-60811-7_10] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]